Breast Cancer TCR-T Cell Therapy

T-cell receptor (TCR-T) cell therapy is an innovative immunotherapeutic strategy that aims to enhance the body's ability to fight breast cancer by utilizing genetically engineered T cells. Alfa Cytology is dedicated to advancing TCR-T cell therapy development specifically for breast cancer.

Introduction of TCR-T Cell Therapy

Breast cancer is the most common cancer in women and the second most common cause of cancer-related death. Engineered adoptive T-cell therapy (E-ACT) is a subset of immunotherapy that equips a patient's T cells with engineered receptors that specifically recognize their cancer. E-ACT can be divided into two major categories: chimeric antigen receptor (CAR) T cell therapy and T cell receptor (TCR) T cell therapy. Both approaches have been used in breast cancer models with varying degrees of success. TCR-T cell therapy utilizes natural TCRs isolated from T cell clones that recognize target tumor antigens. Engineered TCR (E-TCR) T cells can recognize peptides of intracellular and extracellular tumor antigens presented on surface MHC molecules, including neoantigens resulting from tumor-specific mutations. Since TCRs recognize tumor antigens in an MHC-dependent manner, the E-TCR matches the MHC allele expressed by the patient. Some breast cancer cases harbor PIK3CA, TP53, and ESR1 mutations, and the use of E-TCRs targeting these mutations is an attractive therapeutic avenue.

Fig.1 Challenges faced by E-ACT in treating solid malignancies. (Chamorro DF, et al., 2023)

Our Services

Alfa Cytology has a proven TCR discovery and characterization platform. Our workflows include services for target ID, characterization, safety assessment, and non-viral editing methods for manufacturing cell products. This workflow provides customers looking to enter the TCR-T cell therapy space with an integrated process from target identification to commercialized products. Our one-stop TCR-T therapy development services include but are not limited to:

Our Services	Descriptions
TCR Biomarker Identification and Selection	De novo discovery of potential cancer biomarkers through multiple gene and protein analysis techniques Select the most appropriate, more potent, and less toxic TCR-T therapeutic target
TCR Generation and Optimization	TCR generated from patient's TIL, phage display, and in vivo systems TCR affinity optimization/TCR affinity maturation
TCR Design and Construction	Design and construction of classic TCRs with different modifications Custom TCR design TCR-T structure
TCR Gene Packaging and Delivery	Both lentiviral and retroviral vectors are available Virus production for clinical trials and applications Strict quality control
*TCR in Vitro* Assay**	T cell validation assay T cell activation assay Cytokine release assay Cytotoxicity assay TCR specificity assay
*TCR-T Preclinical in Vivo* Testing**	Animal model construction T cell transport test T cell persistence test Efficacy test Safety/toxicity evaluation
TCR Analysis	TCR full spectrum sequencing, TCR Vβ full spectrum analysis, MHC peptide tetramer, MHC tetramer detection, TCR clonality assessment, TCR clonality quantification and CDR3 size diversity technology

Alfa Cytology is a world-leading preclinical CRO company dedicated to assisting scientists around the world in BC research. We can provide you with BC TCR-T Cell Therapy development services and help in the development of therapies and diagnostics for BC. If you have any questions about BC research, please contact us and our experts will get back to you as soon as possible.

Reference

Chamorro DF, et al. Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential. Cancers (Basel). 2023 Dec 26;16(1):124.

All our services are exclusively intended for preclinical research purposes. They are not intended for diagnostic, therapeutic, or patient management applications.